

John Choi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4867190/publications.pdf>

Version: 2024-02-01

24
papers

1,089
citations

623734

14
h-index

713466

21
g-index

24
all docs

24
docs citations

24
times ranked

1937
citing authors

#	ARTICLE	IF	CITATIONS
1	Synergy between glutamate modulation and anti- α -programmed cell death protein 1 immunotherapy for glioblastoma. <i>Journal of Neurosurgery</i> , 2022, 136, 379-388.	1.6	11
2	Sustained localized delivery of immunotherapy to lymph nodes reverses immunosuppression and increases long-term survival in murine glioblastoma. <i>Oncolimmunology</i> , 2021, 10, 1940673.	4.6	7
3	Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma. <i>Oncolimmunology</i> , 2021, 10, 1956142.	4.6	22
4	Combination immunotherapy strategies for glioblastoma. <i>Journal of Neuro-Oncology</i> , 2021, 151, 375-391.	2.9	38
5	PD-1+ Monocytes Mediate Cerebral Vasospasm Following Subarachnoid Hemorrhage. <i>Neurosurgery</i> , 2021, 88, 855-863.	1.1	11
6	Absence of Ischemic Injury after Sacrificing the Superior Petrosal Vein during Microvascular Decompression. <i>Operative Neurosurgery</i> , 2020, 18, 316-320.	0.8	12
7	CLEC5A expressed on myeloid cells as a M2 biomarker relates to immunosuppression and decreased survival in patients with glioma. <i>Cancer Gene Therapy</i> , 2020, 27, 669-679.	4.6	15
8	Nonviral polymeric nanoparticles for gene therapy in pediatric CNS malignancies. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020, 23, 102115.	3.3	35
9	In Vivo Bioluminescence Tomography Center of Mass-Guided Conformal Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 612-620.	0.8	17
10	Safety considerations for nanoparticle gene delivery in pediatric brain tumors. <i>Nanomedicine</i> , 2020, 15, 1805-1815.	3.3	12
11	ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma. <i>Theranostics</i> , 2020, 10, 5943-5956.	10.0	76
12	A systematic review and meta-analysis of supratotal versus gross total resection for glioblastoma. <i>Journal of Neuro-Oncology</i> , 2020, 148, 419-431.	2.9	48
13	Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa011.	0.7	22
14	IMMU-27. SINGLE CELL RNA-SEQUENCING IDENTIFIES NOVEL BONE MARROW DERIVED MYELOID CELLS IN GLIOBLASTOMA ASSOCIATED WITH TUMOR AGGRESSION. <i>Neuro-Oncology</i> , 2020, 22, ii110-ii110.	1.2	0
15	Mechanisms of immunotherapy resistance: lessons from glioblastoma. <i>Nature Immunology</i> , 2019, 20, 1100-1109.	14.5	421
16	The Use of Ribavirin as an Anticancer Therapeutic: Will It Go Viral?. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1185-1194.	4.1	49
17	Overall Survival in Malignant Glioma Is Significantly Prolonged by Neurosurgical Delivery of Etoposide and Temozolomide from a Thermo-Responsive Biodegradable Paste. <i>Clinical Cancer Research</i> , 2019, 25, 5094-5106.	7.0	32
18	A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials. <i>Cancers</i> , 2019, 11, 537.	3.7	66

#	ARTICLE	IF	CITATIONS
19	TMIC-14. PD-L1 EXPRESSION IS NEGATIVELY CORRELATED TO OUTCOMES IN PATIENTS WITH MGMT METHYLATED PROMOTERS IN GBM. <i>Neuro-Oncology</i> , 2019, 21, vi250-vi250.	1.2	0
20	IMMU-18. IMMUNOGENOMIC RESPONDER PHENOTYPE FROM A PHASE I TRIAL OF ANTI-LAG3 OR ANTI-CD137 ALONE AND IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH RECURRENT GBM. <i>Neuro-Oncology</i> , 2019, 21, vi122-vi123.	1.2	1
21	SURG-16. SUPRATOTAL VERSUS GROSS TOTAL RESECTION OF GLIOBLASTOMA: A SYSTEMATIC REVIEW. <i>Neuro-Oncology</i> , 2019, 21, vi243-vi243.	1.2	0
22	Carboxylated branched poly(β -amino ester) nanoparticles enable robust cytosolic protein delivery and CRISPR-Cas9 gene editing. <i>Science Advances</i> , 2019, 5, eaay3255.	10.3	127
23	Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system. <i>Oncolmmunology</i> , 2018, 7, e1500108.	4.6	52
24	Ribavirin as a potential therapeutic for atypical teratoid/rhabdoid tumors. <i>Oncotarget</i> , 2018, 9, 8054-8067.	1.8	15